653. Myeloma: Therapy, excluding Transplantation: Studies in Relapsed and Refractory Multiple Myeloma

Kwee Yong, PhD1*, Samantha Hinsley2*, Holger W. Auner, MD, PhD3*, Debbie Sherratt2*, et al.

The authors conclude that:

Major response (≥VGPR) to KCD therapy is non-inferior to VCD and overall response rate is superior to VCD over a fixed treatment duration. This may be related to better tolerability and reduced incidence of neurotoxicity with KCD, with superiority of KCD in terms of grade ≥3 neuropathy or grade ≥2 neuropathy with pain. Further details on safety and activity will be presented at the meeting.

Vittorio Montefusco, MD1*, Alessandro Corso, MD2*, Monica Galli, MD, PhD3*, Elena Tagliabue4*, Set al.

The authors conclude that:

This is the first head-to-head study comparing fixed duration therapy of Bort and Len in first relapse patients. We show that both drugs are equally effective, in terms of depth of response, PFS, and OS. Despite drug-specific toxicity profiles, incidence of grade III and IV toxicities were not different between the 2 arms.
 

Laurent Garderet, MD, PhD1, Frederique Kuhnowski, MD2*, Jean Yves Mary, MD3*, Murielle Roussel4*, et al.

The authors conclude that:

In this first planned relapse trial, the all oral combination of pomalidomide, cyclophosphamide and dexamethasone was very efficacious at first relapse following lenalidomide, bortezomib and dexamethasone treatment. After 4 cycles, the rate of partial response or better was 91% and 92% of the patients could proceed to ASCT. Toxicity was mostly hematological and manageable. These results should be compared to those of other pomalidomide and dexamethasone-based second line therapies.

Ajai Chari1*, Hareth Nahi2*, Maria-Victoria Mateos, MD, PhD3, Henk M. Lokhorst4*, et al.

The authors conclude that:

SC administration of DARA + rHuPH20 was well tolerated, with lower than expected rates of IRRs in all groups, but particularly in those treated with DARA SC 1800 mg administered over only 3-5 minutes. Planned phase 3 studies will use DARA SC at the dose identified in Part 2.

Robert J Pelham, PhD1*, Xuguang Hu, PhD1*, Philippe Moreau2*, Albert Oriol, MD3*, et al.

The authors conclude that:

We identified a classifier with a set of genes whose baseline expression could potentially be used to stratify RRMM patients for greater treatment benefit with Kd56. As only one patient cohort was used for this study, the classifier identified here should be validated in prospective studies and with independent sets of patient cohorts. Further study of this group of genes may provide additional insights into the biology of multiple myeloma and how mechanism of action differs between carfilzomib and bortezomib.

Sheeba K. Thomas, MD1, Jatin J. Shah, MD2*, Hans C. Lee, MD3, Elisabet E. Manasanch, MD3, et al.

The authors conclude that:

Lenalidomide-elotuzumab is a well-tolerated maintenance therapy on which 44% of 55 pts have had improvement in quality of response while on therapy, including 28% who have converted to CR and 24% who have tested MRD negative. The number of pts who have experienced improvement on study may, in fact, be underestimated in this analysis due to elotuzumab interference with measurement on electrophoretic studies. Additional follow up is required to determine if the improved quality of responses translate into improvements in PFS and OS.